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EpigeneticAbstract MLL-rearranged acute lymphoblastic leukaemia (ALL) in infants is the most
difﬁcult-to-treat type of childhood ALL, displaying a chemotherapy-resistant phenotype,
and unique histone modiﬁcations, gene expression signatures and DNA methylation patterns.
MLL-rearranged infant ALL responds remarkably well to nucleoside analogue drugs in vitro,
such as cytarabine and cladribine, and to the demethylating agents decitabine and zebularine
as measured by cytotoxicity assays. These observations led to the inclusion of cytarabine into
the treatment regimens currently used for infants with ALL. However, survival chances for
infants with MLL-rearranged ALL do still not exceed 30–40%.
Here we explored the in vitro potential of the novel nucleoside analogue clofarabine for
MLL-rearranged infant ALL. Therefore we used both cell line models as well as primary
patient cells. Compared with other nucleoside analogues, clofarabine effectively targeted pri-
mary MLL-rearranged infant ALL cells at the lowest concentrations, with median LC50 val-
ues of 25 nM. Interestingly, clofarabine displayed synergistic cytotoxic effects in
combination with cytarabine. Furthermore, at concentrations of 5–10 nM clofarabine induced
demethylation of the promoter region of the tumour suppressor gene FHIT (Fragile Histidine
Triad), a gene typically hypermethylated in MLL-rearranged ALL. Demethylation of the
FHIT promoter region was accompanied by subtle re-expression of this gene both at the
mRNA and protein level. We conclude that clofarabine is an interesting candidate for further
studies in MLL-rearranged ALL in infants.
 2015 Elsevier Ltd. All rights reserved.a-1611,
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Survival chances for children with acute lymphoblas-
tic leukaemia (ALL) have improved tremendously over
the past decades [1]. Nonetheless, the prognosis for
infants (<1 year of age) with ALL remains dismal
[2,3]. Infant ALL represents a highly aggressive type of
leukaemia characterised by chromosomal translocations
involving the MLL gene (80% of the cases) [4,5], and
typically presents with hepatosplenomegaly, exceedingly
high leucocyte counts, and often shows central nervous
system involvement [6]. Moreover, infant ALL cells usu-
ally are resistant to multiple chemotherapeutic drugs
currently used in paediatric ALL treatment regimens,
especially to glucocorticoids (such as prednisone and
dexamethasone) and L-asparaginase [7,8]. However,
infant ALL cells have proven to be highly sensitive to
the nucleoside analogue cytarabine (i.e. cytosine arabi-
noside, or ara-C) [7,8], which appeared to be associated
with elevated expression of the human equilibrative
nucleoside transporter 1 (hENT1) on which cytosines
are mainly dependent to permeate the cell membrane
[9]. Based on these ﬁndings a unique infant ALL treat-
ment protocol (Interfant-99) was designed, implement-
ing varying dosages of cytarabine throughout the
treatment courses of a standard childhood ALL regimen
[3]. The Interfant-99 treatment protocol appeared suc-
cessful, achieving long-term event-free survival in 47%
of the infant ALL cases, realising superior treatment
results over earlier attempts exploring therapy intensiﬁ-
cation [3].
Recently we demonstrated that MLL-rearranged
infant ALL is characterised by increased levels of
DNA methylation at numerous gene promoters, leading
to suppressed expression of associated genes [10].
Furthermore this study showed that the degree of pro-
moter methylation is associated with the risk of disease
relapse [10]. Interestingly, hypermethylated
MLL-rearranged ALL cells appeared highly responsive
to so-called demethylating agents (e.g. decitabine and
zebularine) [10,11]. Like cytarabine, decitabine and
zebularine are cytidine analogues, but in contrast to
cytarabine, which was originally designed to inhibit
DNA synthesis (Fig. 1A), these agents were speciﬁcally
developed to inhibit DNA methylation. Demethylating
cytidine analogues exert their actions by competing with
normal cytosines for incorporation into the DNA. Once
incorporated, these analogues are able to covalently
bind, and thereby trap, DNA methyltransferases
(DNMTs) during their donation of methyl groups on
receiving cytidines (Fig. 1A). As a consequence, the cell
becomes depleted from functional DNMTs and loses its
ability to methylate the DNA during subsequent cell
cycles [12]. Presumably, the sensitivity of
MLL-rearranged ALL cells to demethylating cytosine
analogues can be ascribed to the aberrant DNAmethylation patterns recently found in this type of leu-
kaemia [10,11], but may certainly be enhanced by the
elevated expression of hENT1 characteristically
observed in infant ALL [9]. Thus, demethylating cyto-
sine analogues embody promising candidates for the
treatment of MLL-rearranged ALL in infants.
Unfortunately, despite several clinical trials demonstrat-
ing biologic activity and clinical responses for both dec-
itabine and azacitidine in adults diagnosed with
myelodysplastic syndromes (MDS) or chronic
myelomonocytic leukaemia (CMML) [13,14], clinical
results in general remain somewhat disappointing
[15,16].
Apart from cytosine analogues, infant ALL cells also
appeared to respond remarkably well to another nucle-
oside analogue, i.e. cladribine [7,8,17]. Although cladrib-
ine represents an adenosine analogue, and as such lacks
the ability to bind DNMTs, it has been reported to pos-
sess methylation-inhibiting properties via an alternative
mechanism involving the inhibition of S-Adenosyl
Homocysteine Hydrolase (SAHH) [18] (Fig. 1B). As a
consequence the amount of intracellular deoxynucle-
oside triphosphates available for DNA replication
becomes impaired, which leads to apoptosis in rapidly
dividing cells. Due to its resistance to inactivation by
deamination or phosphorolysis, clofarabine is more
stable than its predecessors [19]. In addition, clofarabine
was shown to inhibit DNA methylation [20], presum-
ably through a mechanism comparable to that observed
for cladribine (Fig. 1B). A recent study demonstrated
that clofarabine also induces down-regulation of DNA
methyltransferase 1 (DNMT1) at the mRNA level in
chronic myelogenous leukaemia (CML) cells [21].
While clofarabine has proven activity in the treat-
ment of refractory and relapsed childhood ALL [22–
24], we postulate that this agent may be particularly suit-
able for the treatment of infants with ALL, especially in
patients carrying MLL translocations and hypermethy-
lated genomes. Therefore we here compared the cyto-
toxic eﬀects of clofarabine and other nucleoside
analogues on primary MLL-rearranged infant ALL
cells, explored possible synergistic eﬀects between clo-
farabine and cytarabine, and evaluated the potential of
clofarabine to inhibit DNA methylation.
2. Materials and methods
2.1. Patient samples and leukaemic cell isolation
In this study, primary patient samples were used from
both infant (<1 year of age) (n = 10) and paediatric
non-infant (>1 year of age) (n = 10) precursor B-ALL
patients. All infant ALL cases were enrolled in the inter-
national Interfant-99 treatment study [3], and all
non-infant paediatric precursor B-ALL samples were
derived from the Erasmus MC – Sophia Children’s
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Fig. 1. Mechanisms of action and chemical structures of the diﬀerent nucleoside analogue drugs. (A) The cytosine analogues cytarabine (Ara-C), as
well as the demethylating agents decitabine (5-aza-dC) and zebularine, mainly enter the cell via the human equilibrative nucleoside transporter 1
(hENT1). Inside the cell these pro-drugs are sequentially phosphorylated into active nucleoside tri-phosphates (dNTPs) which compete with normal
cytidines for incorporation into the DNA (or RNA) during DNA (and RNA) synthesis. As such, cytarabine blocks RNA and DNA synthesis
leading to apoptosis. In contrast, the demethylating agents decitabine and zebularine do not inhibit DNA synthesis, but covalently bind DNA
methyltransferases (DNMTs) during methylation events. As a result, DNMTs become trapped onto the DNA, depleting the cell from functional
DNMTs and impairing the ability of the cell to distribute methylation in subsequent cell cycles. (B) The adenosine analogues cladribine (2CdA) and
clofarabine (CAFdA), comparable to cytosine analogues, require triple phosphorylations to become eﬀective and incorporated into the DNA.
Apart from inhibition of DNA synthesis, cladribine, and presumably clofarabine as well, block DNA methylation by inhibition of S-Adenosyl
Homocysteine Hydrolase (SAHH), which hydrolyses S-Adenosyl Homocysteine (SAH). The subsequent accumulation of SAH production impairs
the formation of the methyl-donor S-Adenosyl Methionine (SAM) (which is used as a methyl-pool by DNMTs), and thereby inhibits DNA
methylation. Finally, clofarabine also inhibits ribonucleotide reductase (RnR), blocking the formation of normal dNTPs, and as such eliminating
the competition for incorporation into the DNA. (C) Shows the chemical structures of cytidine and the cytidine analogue drugs cytarabine,
decitabine and zebularine. The diﬀerence between normal cytidines and cytarabine is the inversion of 20hydroxyl groups from a trans position in
cytidine to a cis conﬁguration in cytarabine. Decitabine lacks the 20hydroxyl group and carries an additional nitrogen in its base. Zebularine
essentially shares its structure with cytarabine, but lacks the amino-group in its base. (D) Shows the chemical structures of adenosine and the
adenosine analogues cladribine and clofarabine. Compared with normal adenosine, cladribine carries a chloro-group in its base. Apart from the
chloro-group, clofarabine has an additional ﬂuoro group present at the 30-position of its ribose moiety. Abbreviations used: Ara-C = cytarabine, 5-
aza-dC = decitabine, 2CdA = cladribine, and CAFdA = clofarabine.
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ples were selected based on the presence of t(4;11), the
most common MLL translocation found among infant
ALL patients [3]. Positivity for t(4;11) was assessed by
split-signal FISH and RT-PCR analysis. None of the
paediatric non-infant ALL samples was positive for
t(4;11). Informed consent was obtained from the parents
or legal guardians according to the recommendations of
the Helsinki declaration, and approved by the
Institutional Review Board of the Erasmus University
Medical Center.
Primary bone marrow or peripheral blood samples
were obtained before treatment, and mononuclear cells
were isolated using sucrose density-gradient centrifuga-
tion (density 1.077 g/ml; Lymphoprep, Nycomed
Pharma, Oslo, Norway) within 24 h of sampling. Cells
were resuspended in RPMI 1640 medium (Invitrogen
Life Technologies, Breda, the Netherlands) supple-
mented with 20% foetal-calf serum (FCS; Integro,
Zaandam, the Netherlands), 2 mM L-glutamine,
5 lg/mL insulin, 5 lg/mL transferrin, 5 ng/mL sodium
selenite (ITS media supplement; Sigma, St Louis, MO,
United States of America (USA)), 200 lg/mL gen-
tamycin (Invitrogen Life Technologies, Breda, the
Netherlands), 100 IU/mL penicillin, 100 lg/mL strepto-
mycin and 0.125 lg/mL fungizone (Invitrogen Life
Technologies, Breda, the Netherlands). When necessary,
contaminating non-leukaemic cells were removed using
immunomagnetic beads (DynaBeads, Dynal Inc., Oslo,
Norway) as previously described [25]. As a result, all leu-
kaemic samples used in this study contained more than
90% of leukaemic blasts.
2.2. Leukaemia cell lines
The cell lines SEM and RS4;11 were used as models
for MLL-rearranged B-ALL. Both cell lines carry
translocation t(4;11). SEM was originally derived from
a 5-year-old girl at relapse [26] and RS4;11 was estab-
lished from the bone marrow of a 32-year-old woman
in ﬁrst relapse [27]. The cell lines were purchased from
the German Collection of Microorganisms and Cell
Cultures (DSMZ, Braunschweig, Germany), and main-
tained as suspension cultures in RPMI 1640 with
L-Alanyl-L-Glutamine (Invitrogen Life Technologies,
Breda, the Netherlands) supplemented with 10% FCS
(Integro, Zaandam, the Netherlands), 100 IU/mL peni-
cillin, 100 lg/mL streptomycin and 0.125 lg/mL fungi-
zone (Invitrogen Life Technologies, Breda, the
Netherlands) at 37 C in humidiﬁed air containing 5%
CO2.
2.3. In vitro cytotoxicity assays and nucleoside analogue
exposure
The in vitro sensitivity of leukaemia cells to decitabine
(Sigma–Aldrich, Zwijndrecht, the Netherlands),zebularine (kindly provided by Dr. Victor E. Marquez,
National Cancer Institute of Frederick, Frederick,
MD, USA), cladribine (Sigma–Aldrich, Zwijndrecht,
the Netherlands), cytarabine (Cytosar, Pharmacia BV,
Woerden, the Netherlands) and clofarabine (Genzyme
Europe, Naarden, the Netherlands), was determined
by 4-day MTT-assays as described previously [28].
Brieﬂy, leukaemic cells were cultured in the absence or
presence of varying concentrations of the above men-
tioned nucleoside analogues for four days, and drug sen-
sitivity was expressed as the LC50 value (i.e. the
concentration of nucleoside analogue drug lethal to
50% of the leukaemic cells) or, in the case of cell lines
as the IC50 value (i.e. the concentration of nucleoside
analogue drug inhibitory to 50% of the leukaemic cells).
Each experiment was performed in duplicate, and car-
ried out at least twice.
The eﬀects of the hENT1 inhibitor NBMPR
(S-(4-Nitrobenzyl)-6-thioinosine (NBMPR, Sigma–
Aldrich, Zwijndrecht, the Netherlands) on clofarabine
and cytarabine cytotoxicity were evaluated by perform-
ing standard MTT assays in the presence of 3 lM of
NMBPR, both in the control cells (untreated cells)
and cells exposed to clofarabine or cytarabine.
In order to investigate whether the combination of
cytarabine and clofarabine evoked either antagonistic
or synergistic cytotoxic eﬀects, cytarabine cytotoxicity
(4-day MTT assays) was determined in the t(4;11)-posi-
tive cell line SEM in the absence and presence of 0.5 or
10 nM clofarabine. For this, cells were pre-incubated
with 0.5 or 10 nM clofarabine prior to the actual MTT
assay for cytarabine (during which clofarabine remained
present throughout the entire experiment). Likewise,
clofarabine cytotoxicity was determined in the absence
and presence of 25 or 50 nM cytarabine. For all concen-
trations of cytarabine and clofarabine treatment, a
hypothetical maximum additive eﬀect was calculated
using the following equation A  B/100, in which A
and B indicate survival values with single agents. In case
the actual product of cell viability of combined cytara-
bine/clofarabine treatment reﬂected the calculated
value, the eﬀects were considered additive. When the
actual value was lower than the calculated value, the
eﬀect was deemed synergistic.
2.4. Isolation and puriﬁcation of DNA and RNA
Genomic DNA and total cellular RNA were
extracted from a minimum of 5  106 cells using the
DNeasy Blood and Tissue Kit and the RNeasy mini
Kit (Qiagen Benelux BV, Venlo, the Netherlands)
according to the manufacturer’s protocol. The quality
of the extracted DNA was assessed on 1.5% agarose
gels, and the RNA integrity was determined using
RNA 6000 Nano Assay LabChips on the Agilent
2100 Bio-analyser (Agilent Technologies, Santa
Clara, CA, USA).
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methylation analysis
Genomic DNA was bisulphite converted using the
EZ DNA methylation kit (Zymo Research
Corporation, CA, USA) according to the manufac-
turer’s instructions. Bisulphite treatment of the DNA
converts non-methylated cytosine bases to uracil (which
is replaced by thymine during subsequent PCR cycles),
but does not aﬀect 5-methylcytosine residues, allowing
discrimination of methylated or unmethylated cytosines
[29]. To quantitatively determine the levels of methyla-
tion at given loci, we subsequently applied pyrosequenc-
ing. In contrast to traditional Sanger sequencing,
pyrosequencing is a ‘sequencing by synthesis’ based
method that relies on the detection of DNA polymerase
activity (visualised by pyrophosphate release during
nucleotide incorporation). Essentially, this technique
allows sequencing of a single DNA strand by base per
base synthesis of the complementary strand, while mon-
itoring which nucleotide was actually added. As such,
pyrosequencing can be used to quantitatively assess
the level of methylation in a bisulphite treated DNA
strand by comparing the cytosine/thymine ratios incor-
porated at selected CpGs [29].
Approximately 20 ng of bisulphite converted DNA
was ampliﬁed using bisulphite-speciﬁc primers ﬂanking
the CpG island within the promoter of the Fragile
Histidine Triad (FHIT) gene. For this, primers were
designed using the Pyrosequencing Assay Design
Software (Qiagen Pyrosequencing Inc.), and the
sequences were as follows, forward primer:
50-GGGGAGGTAAGTTTAAGTGGAATATT-30, (biotiny-
lated) reverse primer: 50-ATCCCCACCCTAAAACCC
TC-30. The PCR product ampliﬁed using this primer
pair includes ﬁve separate CpGs within the FHIT pro-
moter sequence. Ampliﬁcation was performed in the
presence of 4 mM of MgCl2 using a touchdown PCR
with the annealing temperature decreasing from 71 C
to 64 C over 14 cycles of annealing for 1 min, and sub-
sequent denaturation for 15 s at 95 C. The PCR was
completed by 30 cycles of annealing at 64 C for
1 min, and denaturation for 15 s at 95 C. Buﬀers and
hotstart Taq polymerase used for PCR were obtained
from the Qiagen Pyromark PCR kit (Qiagen
Pyrosequencing, Inc.). Ampliﬁed PCR products were
initially analysed on 2% agarose gels. Then, PCR prod-
ucts were denatured and antisense strands (containing
biotin labels) were bound to Streptavidin Sepharose
HP (Amersham Biosciences). Immobilised PCR strands
coupled to the Sepharose beads were puriﬁed, washed
and denatured using a 0.2 M NaOH solution. Next,
0.3 lM of pyrosequencing primer (50-AAGTTTAAGTG
GAATATTGT-30) was annealed to the puriﬁed
single-stranded PCR product and the sequencing reac-
tion was performed in duplicate and analysed on aPyroMark MD system (Qiagen Pyrosequencing, Inc.).
Conﬁrmation of complete bisulphite conversion was
assessed by a cytosine/thymine control that was inte-
grated in the FHIT CpG island assay. Subsequent quan-
tiﬁcation of methylation density on selected CpGs was
performed using the Pyro Q-CpG software (Qiagen
Pyrosequencing, Inc.). The degree of methylation in
the FHIT CpG sequence was determined from the ratio
of thymine and cytosine nucleotides and is presented as
the number of methylated cytosine nucleotides divided
by the amount of methylated and unmethylated
cytosines  100%.2.6. Quantitative real-time PCR analysis
Total RNA was reverse transcribed as described pre-
viously [9] and the obtained cDNA was used to quantify
mRNA expression using quantitative real-time PCR
analysis as described elsewhere [30]. All oligonucleotides
were designed using the OLIGO 6.22 software
(Molecular Biology Insights, Cascade, CA, USA).
Primer combinations used for transcript ampliﬁcation
of the FHIT target gene as well as the housekeeping ref-
erence gene GAPDH (encoding glyceraldehyde-3-
phosphate dehydrogenase) have earlier been published
[31]. PCR products were ampliﬁed using the DyNAmo
SYBR Green qPCR kit (Finnzymes, Espoo, Finland)
according to the manufacturer’s recommendations,
using SYBR Green as a ﬂuorophore to detect ampliﬁed
transcripts. Per experiment samples were analysed in
duplicate and all experiments were conducted twice.2.7. Western blotting
Whole cell protein lysates containing 25 lg of protein
were resolved on 10% polyacrylamide gels topped with
4% stacking gels, and subsequently transferred to nitro-
cellulose membranes (Schleicher & Schuell, Dassel,
Germany). The membranes were then probed with the
following antibodies: rabbit polyclonal anti-FHIT
(Millipore, Billerica, MA, USA, #07-172), or rabbit
polyclonal anti-DNMT1 (New England Biolabs,
Ipswich, MA, USA, #M0231S). Anti-beta-Actin mouse
monoclonal antibodies (Abcam, Cambridge, USA,
#ab6276) were used to detect beta-Actin and conﬁrm
equal loading in all lanes. Upon incubation (protected
from light) with infrared-labelled secondary antibodies
(IRDye 800CW goat-anti-rabbit antibody
(#926-32211, LI-COR, Lincoln, NE) and IRDye 680
goat-anti-mouse antibody (#926-32220, LI-COR,
Lincoln, NE)) in 5% milk, the membranes were washed
in phosphate-buﬀered saline (PBS) containing 0.1%
Tween-20 (Merck Schuchardt OHG, Hohenbrunn,
Germany). Finally the membranes were scanned using
an Odyssey Infrared Imaging System (LI-COR Inc.,
D.J.P.M. Stumpel et al. / European Journal of Cancer 51 (2015) 2008–2021 2013Lincoln, NE, USA), and protein expression was quanti-
ﬁed using the Odyssey software.2.8. Statistical analysis
Diﬀerences in LC50 values between MLL-rearranged
infant precursor B-ALL and non-infant paediatric pre-
cursor B-ALL samples were evaluated using two-tailed
Mann–Whitney U tests (performed in SPSS 17.0 statisti-
cal software), and considered statistically signiﬁcant at
p-values <0.05. Graphpad Prism graphical software ver-
sion 5 (La Jolla, CA, USA) was used for data
visualisations.3. Results
3.1. Infant ALL cells are highly sensitive to nucleoside
analogues, including clofarabine
Although MLL-rearranged infant ALL cells usually
are resistant to multiple chemotherapeutic drugs, these
cells often are highly sensitive to nucleoside analogue
drugs including cytarabine and cladribine [7–9], and
the demethylating cytosine analogues zebularine [10]
and decitabine [11]. Here we explored the potential of
the new-generation nucleoside analogue clofarabine in
MLL-rearranged infant ALL. Fig. 1C–E shows the
chemical structures of the cytosine analogues cytara-
bine, decitabine and zebularine, and the adenosine ana-
logues cladribine and clofarabine. We compared the
eﬀects of these nucleoside analogues on cell death and
proliferation in the MLL-rearranged ALL cell lines
SEM and RS4;11. As shown in Fig. 2A and B, eﬀective
concentrations are convincingly lower for both adeno-
sine analogues as compared with the cytosine analogues.
The lowest IC50 values were observed for clofarabine,
with inhibiting concentrations of 3.5 nM and 5 nM for
RS4;11 and SEM respectively (Fig. 2A and B).
Next, we compared the LC50 values of cytarabine,
cladribine and clofarabine in primary samples from
MLL-rearranged infant ALL patients (n = 10), all car-
rying translocation t(4;11), and non-infant paediatric
precursor B-ALL patients (n = 10). Unfortunately, the
demethylating agents zebularine and decitabine could
not be tested on primary patient material, as these com-
pounds require several cell divisions to become eﬀective,
and primary ALL cells generally stop proliferating once
outside the patient’s body. Although the other nucle-
oside analogues also require cell cycles to become incor-
porated into the genomic DNA, multiple studies have
demonstrated that in vitro cytarabine and cladribine
cytotoxicity can be induced in non-dividing patient cells
[9,32], for example by inhibition of RNA synthesis [32].
As expected from earlier studies, MLL-rearranged
infant ALL cells are signiﬁcantly more sensitive to
cytarabine (2-fold diﬀerence, p = 0.001) (Fig. 2C)and cladribine (1.4-fold diﬀerence, p = 0.005) (Fig. 2D)
compared with non-infant paediatric precursor B-ALL
cells. Interestingly, MLL-rearranged infant ALL cells
also appeared marginally (although not signiﬁcantly)
more sensitive to clofarabine (1.7-fold diﬀerence,
p = 0.075) (Fig. 2E). Clofarabine eﬀectively induced leu-
kaemic cell death in primary ALL samples at average
LC50 values as low as 15–30 nM, while similar eﬀects
for cytarabine required 1–2.5 lM (Fig. 2C–E).3.2. Sensitivity to clofarabine is not dependent on the
hENT1 transporter
In a previous study we investigated the mechanism
underlying cytarabine sensitivity in MLL-rearranged
infant ALL cells, and found that these cells express sig-
niﬁcantly higher levels of the human equilibrative nucle-
oside transporter 1 (hENT1) [9], on which cytarabine is
mainly dependent to permeate the cell membrane [33].
Therefore, we asked whether clofarabine sensitivity
may also be dependent on hENT1 by measuring
the eﬀects of the hENT1 inhibitor NBMPR
(S-(4-Nitrobenzyl)-6-thioinosine) (which signiﬁcantly
inhibits cytarabine inﬂux and toxicity at 1–3 lM [33]),
on clofarabine cytotoxicity. 3 lM of NBMPR itself did
not induce any in vitro cytotoxicity in MLL-rearranged
ALL cells. As shown in Fig. 3A, 3 lM of NBMPR
markedly inhibited the cytotoxic eﬀects for cytarabine
in the t(4;11)-positive ALL cell line SEM, whereas the
eﬀects on clofarabine cytotoxicity were far less pro-
nounced (Fig. 3B). Next we evaluated the eﬀects of
NBMPR on cytarabine and clofarabine cytotoxicity in
two t(4;11)-positive infant ALL patient samples. These
experiments showed that blocking hENT1 using
NBMPR reduces the cytotoxic eﬀects of cytarabine
(Fig. 3C and D), but does not aﬀect the in vitro
responses to clofarabine (Fig. 3E and F).3.3. Additive/synergistic cytotoxic eﬀects for clofarabine
and cytarabine in MLL-rearranged ALL
The ﬁrst observation that infant ALL cells are highly
sensitive to cytarabine [7] led to the successful imple-
mentation of cytarabine courses in the infant ALL treat-
ment protocol Interfant-99 [3]. However, with a new
nucleoside analogue like clofarabine already available
for clinical testing, and capable of targeting leukaemic
cells at nanomolar concentrations, important questions
should be asked: Should cytarabine be replaced by clo-
farabine, or would MLL-rearranged infant ALL
patients further beneﬁt from the addition of clofarabine
to existing treatment protocols? Interestingly, synergy
between clofarabine and cytarabine has been described
both in vitro and in vivo [34,35].
To determine whether these nucleoside analogues
also work synergistically in MLL-rearranged ALL, we
Fig. 2. In vitro cytotoxicity of MLL-rearranged ALL cells to diﬀerent nucleoside analogue drugs. (A and B) Dose–response curves showing the
in vitro cytotoxic response (as determined by 4-day MTT assays) to the nucleoside analogue drugs clofarabine, cladribine, cytarabine, decitabine
and zebularine in the cell lines (A) SEM, and (B) RS4;11. Error bars represent standard errors of the mean (SEM). The IC50 values (concentrations
inhibitory to 50% of the cells) for clofarabine are indicated by grey arrows. (C–E) Comparison of the in vitro drug response (as determined by 4-day
MTT assays) in primaryMLL-rearranged infant ALL (n = 10) and non-infant germline-MLL paediatric precursor B-ALL (n = 10) samples for the
nucleoside analogue drugs (C) cytarabine, (D) cladribine and (E) clofarabine. Drug sensitivity is expressed as LC50 values (concentrations lethal to
50% of the cells). The lines indicate the median LC50 values in each patient group, and diﬀerences in drug response were statistically evaluated by
Mann–Whitney U tests.
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10 nM of clofarabine, as well as clofarabine cytotoxicity
in the presence of 25 or 50 nM of cytarabine in the
t(4;11)-positive cell line SEM. As shown in
Fig. 4A and B, the cytotoxic eﬀects of both drugs are
markedly larger in each others’ presence, especially at
low dosages. However, true synergy exists when the
cytotoxic eﬀects of both agents tested simultaneously
exceed the combined eﬀect of both agents tested individ-
ually. As shown in Fig. 4C, strong synergistic eﬀects
were observed at 5 nM and 10 nM of clofarabine in
combination with 50 nM of cytarabine, but only in case
cells were pre-incubated with cytarabine (also see: mate-
rial and methods). Four days of culturing SEM cells
with a combination of 50 nM cytarabine/5 nM clofara-
bine and 50 nM cytarabine/10 nM clofarabine resulted
in viable cell counts of 33% and 25% respectively.
The calculated product derived from the eﬀects of both
agents when tested separately predicted viable cellcounts for the combination of both drugs of 80%
and 55% respectively. However, the actual combina-
tions of 50 nM cytarabine/5 nM clofarabine and
50 nM cytarabine/10 nM clofarabine resulted in viable
cell counts of 33% and 25% respectively. Yet, when
the same combinations of clofarabine and cytarabine
were tested in which clofarabine was added ﬁrst (1 h
pre-incubation), the synergistic eﬀects were either absent
or only marginally detectable (Fig. 4C).
3.4. Inhibition of DNA methylation by clofarabine
Clofarabine is thought to inhibit DNA methylation
through either inhibition of S-Adenosyl Homocysteine
Hydrolase (SAHH) as shown for cladribine [18], or sup-
pression of DNA methyltransferase 1 (DNMT1) expres-
sion [21]. The demethylating cytosine analogues
zebularine and decitabine inhibit DNA methylation by
replacing normal cytosines in the genomic DNA where
Fig. 3. Eﬀects of NBMPR on cytarabine and clofarabine cytotoxicity inMLL-rearranged ALL cells. TheMLL-rearranged ALL cell line SEM was
pre-incubated for 1 h with or without 3 lM of the pharmacological hENT1-inhibitor NBMPR prior to determining (A) cytarabine, and (B)
clofarabine cytotoxicity using 4-day MTT assays. (NBMPR remained present throughout the experiment). Similarly, (C and D) cytarabine and (E
and F) clofarabine cytotoxicity was determined in two primary t(4;11)-positive infant ALL patient samples in the absence and presence of NBMPR
(3 lM).
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Fig. 4. Evaluation of synergy between cytarabine and clofarabine cytotoxicity in the cell line SEM. (A) The MLL-rearranged ALL cell line SEM
was pre-incubated for 1 h in the absence or presence of either 5 nM or 10 nM clofarabine before initiating 4-day MTT assays to determine
cytarabine cytotoxicity (clofarabine remained present throughout the entire experiment). (B) Likewise, SEM cells were pre-incubated for 1 h in the
absence or presence of either 25 nM or 50 nM cytarabine before 4-day MTT assays were performed using low concentrations of clofarabine
(cytarabine remained present throughout the entire experiment). (C) Shows the leukaemic cell viability after 4-day exposures to cytarabine and/or
clofarabine. Black bars indicate SEM cell viabilities in response to cytarabine or clofarabine alone at indicated concentrations. Dark grey bars
represent the hypothetical additive eﬀects of the cytarabine and clofarabine combined as predicted from the actual exposures of these agents
individually (see: black bars). White and light grey bars show the cell viabilities of the actual combined exposures of cytarabine and clofarabine
tested simultaneously. Cytarabine is abbreviated as ‘cyt’, and clofarabine as ‘clof’. Calculated is abbreviated as ‘calc’. Additive eﬀects are indicated
by: *a, and synergistic eﬀects are marked by: *s.
2016 D.J.P.M. Stumpel et al. / European Journal of Cancer 51 (2015) 2008–2021they covalently bind and trap DNMTs, thereby impair-
ing the ability of the cell to methylate CpGs in consecu-
tive cell cycles [12].
Depletion of cellular DNMT is therefore commonly
used as a reliable read-out for demethylation [36].
Depletion of functional DNMT1 usually is already
observed after 24 h of cell exposure to 0.5 lM ofdecitabine or 100 lM of zebularine (Fig. 5A and B).
In contrast, the DNMT1 binding capacity of both
agents appeared to be largely diminished at nanomolar
concentrations (Fig. 5A and B). As clofarabine
appeared eﬀective at 5–10 nM, we assessed its ability
to deplete DNMT1 at these concentrations. As shown
in Fig. 5C, DNMT1 protein expression seems very
D.J.P.M. Stumpel et al. / European Journal of Cancer 51 (2015) 2008–2021 2017moderately reduced after 7–10 days, but certainly not to
the extent that inhibition of methylation as a result of
DNMT1 depletion may be expected.
Although direct DNMT1 depletion by clofarabine
appears an unlikely mechanism by which this agent inhi-
bits DNA methylation, clofarabine-induced demethyla-
tion remains possible through alternative actions.
Therefore, we further investigated demethylation as a
measure of re-expression of the FHIT gene, known to
be silenced by promoter methylation in MLL-rearranged
ALL cells [31], in response to clofarabine exposure.
Using a quantitative bisulphite pyrosequencing assay
speciﬁcally designed for the FHIT promoter CpG island,
we quantitatively analysed the level of FHIT promoter
CpG methylation in SEM cells in the absence and pres-
ence of decitabine (0.5 lM), zebularine (100 lM) and
clofarabine (5 or 10 nM). As expected, both the
demethylating agents decitabine and zebularine induced
pronounced demethylation of three out of the ﬁve
interrogated CpG loci within the FHIT promoter atdecitabine (0.5 μM):
D0 D1  D3 D7 D10      D0  D1 D3  D7 D10           
SEM                         RS4;11
DNMT1
β-Acn
decitabine (10 nM): DNMT1
β-Acn
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zebularine (100 μM):
D0  D1 D3 D7 D10      D0  D1 D3  D7 D10           
SEM                         RS4;11
DNMT1
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β-Acn
C 
Fig. 5. Cellular DNMT1 depletion induced by nucleoside analogues.
Western blot analysis demonstrating protein expression of DNMT1 in
the cell lines SEM and RS4;11 in the absence or presence of the
demethylating cytidine analogues (A) decitabine and (B) zebularine,
and for the adenosine analogue (C) clofarabine at indicated concen-
trations and progressing exposure times (expressed in days). Beta-actin
was used as a control for equal loading.concentrations of 0.5 lM and 100 lM respectively
(Fig. 6A). At a concentration of 10 nM neither decita-
bine nor zebularine appeared capable of demethylating
the FHIT promoter, although a modest and temporary
response was observed for 10 nM of decitabine after
24 h of exposure (Fig. 6A). Interestingly, 5 nM or
10 nM of clofarabine induced demethylation of the same
CpGs to a comparable extent as 0.5 lM decitabine and
100 lM zebularine, demonstrating that clofarabine
indeed is capable of CpG demethylation at nanomolar
concentrations (Fig. 6A).
Next, we investigated whether demethylation of these
FHIT promoter CpGs as induced by decitabine, zebu-
larine and clofarabine also led to the re-activation of
mRNA and protein expression. As shown in Fig. 6B,
SEM cells exposed to 0.5 lM decitabine or 100 lM
zebularine showed 3 to 4-fold increases in FHIT
mRNA expression at day 7. Clofarabine (5 nM or
10 nM) showed a >2-fold increase in FHIT expression
at the mRNA level (Fig. 6B). At the protein level,
FHIT was most convincingly re-expressed in response
to 0.5 lM decitabine and 100 lM zebularine. At
nanomolar concentrations these agents did not show
re-activation of FHIT protein expression. In contrast,
5 or 10 nM of clofarabine appeared induced subtle but
detectable re-expression of FHIT protein (Fig. 6C).4. Discussion
While the pathophysiology underlying MLL-
rearranged infant ALL is slowly being unraveled, it
remains the genetic subtype of ALL with the worst
clinical outcome. We here showed that clofarabine, a
next generation adenosine analogue, is capable of
demethylating aberrant gene promoter methylation in
MLL-rearranged infant ALL cells. This conﬁrms earlier
observations by Zhang et al. who demonstrated that clo-
farabine displays demethylating properties in lymphoma
cells [22]. Inhibition of aberrant DNA methylation may
become very important in the treatment for
MLL-rearranged infant ALL, as we recently showed
that the majority of these patients display abnormal
genome-wide DNA methylation patterns [10]. While
the clinical eﬀectiveness of the more conventional
demethylating cytosine analogues like decitabine and
zebularine is not fully convincing [15,16], clofarabine
may provide an alternative. Especially since we here
show that primary MLL-rearranged infant ALL cells
are highly sensitive to clofarabine in vitro, which evokes
cell death in 50% of the leukaemic cells at concentrations
as low as 25 nM. At the same time, our present study
showed that 5–10 nM of clofarabine seems suﬃcient to
trigger gene promoter demethylation and re-expression
of the aﬀected gene. Although the demethylating eﬀects
of clofarabine appear modest in comparison with the
demethylating agents decitabine and zebularine, it must
A  
+      D0         D1      D3       D7    D10              
FHIT 
β-Acn 
decitabine (0.5 μM): 
decitabine (10 nM): FHIT 
β-Acn 
FHIT 
β-Acn 
zebularine (100 μM): 
zebularine (10 nM): FHIT 
β-Acn 
FHIT 
β-Acn 
clofarabine (5 nM): 
clofarabine (10 nM): FHIT 
β-Acn 
B            C  
Fig. 6. Demethylation and re-expression of the FHIT gene and protein by nucleoside analogues. (A) Sensitivity of ﬁve individual CpGs within the
FHIT gene promoter to demethylation by indicated nucleoside analogues at depicted concentrations as determined in the MLL-rearranged ALL
cell line SEM. The progression of CpG demethylation was assessed at day 0 (untreated; black lines), at day 3 (dark grey lines) and day 7 (light grey
lines). (B) Quantitative Real-time PCR analysis showing the relative mRNA expression levels of the FHIT gene in the cell line SEM before and after
exposure to the diﬀerent nucleoside analogues decitabine, zebularine and clofarabine at indicated concentrations and time points. (C) FHIT protein
expression levels in the MLL-rearranged ALL cell line SEM in the absence or presence of decitabine, zebularine, or clofarabine at indicated
concentrations and exposure periods. Beta-actin was used as a control for equal loading.
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gle dosage of each agent. In order to be clinically eﬀec-
tive, demethylating agents generally require the
administration of multiple dosages over relatively long
periods of time. Therefore, the demethylating properties
of clofarabine may well be more pronounced at repeated
or continued administrations. Nonetheless, whether
demethylation by clofarabine would actually contribute
to the remarkably good cytotoxic response as here
observed in primary MLL-rearranged infant ALL cells
in vitro remains to be conﬁrmed. Yet, the sensitivity of
this aggressive type of leukaemia to clofarabine is
promising and encouraging in terms of clinical imple-
mentation of this drug in MLL-rearranged infant ALL
treatment regimes. In fact, a recent study using clofara-
bine in heavily pretreated paediatric ALL patients,
included ﬁve MLL-rearranged infant ALL cases of
which three patients achieved complete remission on
clofarabine treatment [23].
Another important ﬁnding in our study is the obser-
vation that clofarabine and cytarabine have a synergistic
cytotoxic eﬀect on MLL-rearranged ALL cells. These
data are in concordance with previously published data
on myeloid leukaemia cells [34] although the concentra-
tions used in our study were signiﬁcantly lower. From
this point of view, addition of clofarabine to
cytarabine-based treatment protocols may seem a highly
attractive treatment option, especially since cytarabine
has been successfully included in the treatment of infant
ALL [3]. Addition of clofarabine, eﬀectively targeting
MLL-rearranged ALL cells as a single agent at nanomo-
lar concentrations, may not only be very beneﬁcial, but
it may also allow the decrease of cytarabine dosages
without losing its required cytotoxic eﬀects.
Clofarabine may also kill a portion of cells
non-responsive to cytarabine [37]. In a clinical setting,
the combined use of clofarabine and low-dose cytara-
bine has already proven eﬀective in adult and paediatric
leukaemias without MLL translocations [35,38].
Studies have revealed that, besides abnormal DNA
methylation, MLL-rearranged leukaemias are linked to
and sustained by aberrant activity of the histone methyl-
transferase DOT1L [39]. Preclinical studies using potent
and selective inhibitors of DOT1L have demonstrated
successful killing of the leukaemic clone in animal mod-
els [39]. The ﬁrst clinical trial using a DOT1L inhibitor
has been initiated. Interestingly, DOT1L inhibitors have
shown to work synergistically with demethylating agents
and with cytarabine in the killing of MLL-rearranged
leukaemia cells [40]. No data exist on the combination
of a DOT1L inhibitor and clofarabine. Most likely, a
combination of drugs is needed to tackle the erroneous
epigenetic landscape of MLL-rearranged infant ALL.
We here demonstrate that clofarabine has signiﬁcant
cytotoxic eﬀects on MLL-rearranged ALL cells from
infants. In addition, it has demethylating eﬀects on thesecells. Pre-incubation and co-incubation with cytarabine
induced synergistic cytotoxicity with clofarabine. We
conclude that clofarabine, either as a single agent, or
in combination with other promising drugs, is an inter-
esting candidate for further studies in MLL-rearranged
infant ALL.
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